In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

Chinmay Jani, MD, discusses findings highlighting how alcohol-related cancer mortality has risen sharply over the past few decades. :19

Rachel I. Vogel, PhD, provides and overview on factors contributing to the time burden cancer care places on patients. 3:02

Alexander D. Sherry, MD, discusses how improvements in OS or quality of life after phase 3 oncology trials are based on improvements in unvalidated alternative endpoints. 4:41

Lucas A. Mavromatis, ScB, discusses findings on how GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes. 7:20

Sonali M. Smith, MD, talks with Oncology Overdrive host Shikha Jain, MD, about presentations on lymphoma at this year’s ASCO meeting. 9:57

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20250531/study-reveals-shocking-rise-in-alcoholrelated-cancer-deaths

https://www.healio.com/news/hematology-oncology/20250603/time-burden-people-with-cancer-face-often-vastly-underestimated

https://www.healio.com/news/hematology-oncology/20250604/few-phase-3-oncology-trials-demonstrate-improvements-in-os-quality-of-life

https://www.healio.com/news/hematology-oncology/20250522/glp1-receptor-agonists-confer-modest-protection-against-obesityrelated-cancers

https://www.healio.com/news/hematology-oncology/podcasts/oncology-overdrive/episode-119

Exercise described as ‘novel, first-in-class’ colon cancer therapy

Source: Booth CM, et al. Abstract LBA3510. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

At-home intervention has potential to enhance cancer care delivery, outcomes

Source: Nipp RD, et al. Abstract 11003. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

Disclosures:

Jani reports no relevant financial disclosures.

Mavromatis reports no relevant financial disclosures.

Sherry reports honoraria from Sermo.

Smith reports no relevant financial disclosures.

Vogel reports a consulting/advisory role with Voluntis.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2025 American Academy of Neurology Annual Meeting.

Mary A. O'Neal, MD, FAAN, and Ratna K. Bhavaraju-Sanka, MD, FAAN, discuss their efforts to address the lack of access to neurological care by partnering with primary care. :34

Merit E. Cudkowicz, MD, MSc, FAAN, speaks with Healio about being honored The American Academy of Neurology’s Lifetime Achievement Award for her extensive work in ALS research. 2:50

Read the full coverage here:

https://www.healio.com/news/neurology/20250417/partners-in-crime-neurologists-collaborate-with-pcps-to-improve-brain-health

https://www.healio.com/news/neurology/20250407/merit-e-cudkowicz-md-msc-receives-lifetime-award-for-als-research-im-not-done-yet

ACCORD-2: AXS-05 delays relapse time to Alzheimer’s disease agitation

Source: Grossberg G, et al. Efficacy and safety of AXS-05 in Alzheimer's disease agitation: Results from ACCORD-2, a phase 3 randomized withdrawal double-blind placebo-controlled study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Risk for ARIA driven by patient genotype, presence of hemorrhage in early Alzheimer’s

Source: Biffi A, et al. ARIA insights from the donanemab trials: Amyloid-targeted therapy in early symptomatic Alzheimer’s disease. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Microplastics in oceans may increase disability risk among coastal populations

Source: Ganatra S, et al. Marine microplastics levels and the prevalence of neurologic disability. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Nightmares may increase risk for early death

Source: Otaiku A, et al. Distressing dreams and risk of premature mortality: A population-based multicohort study. Presented at: American Academy of Neurology Annual Meeting; April 5-9, 2025; San Diego.

Disclosures:

Bhavaraju-Sanka reports serving as a consultant for Amgen and Argenx.

Cudkowicz reports financial relationships with AB Science, AC Immune SA, Aclipse, Annals of Neurology, Biogen, Coya Therapeutics, Cytokinetics, Eli Lilly, Immunity Pharma, InFlectis, Locust Walk, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Pasithea Therapeutics, Pontifax, Praxis Precision Medicine, Transposon, QurAlis, Regeneron, VectorY. She also reports receiving publishing royalties from a publication relating to health care. Her institution(s) received support from ALS Finding a Cure, ALS ONE, Biohaven, Calico, Clene Nanomedicine, Denali, ITB, Johnson & Johnson, the National Institute of Neurological Disorders and Stroke, PharmAust, Prilenia, Seelos, UCB/RA and Woolsley.

O’Neal reports serving as a consultant and excerpt witness for Circo; being an employee of Best Doctors; and receiving publishing royalties from a health care-related publication.

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio’s top headlines from the meeting.

Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24

Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29

Moath Albliwi, MD, discusses the results of a study he co-presented examining treatment of elderly patients with acute myeloid leukemia. 00:00

Alexey Danilov, MD, PhD, reviews the efficacy of epcoritamab among heavily pretreated patients with advanced chronic lymphocytic leukemia. 00:00

Lee Greenberger, PhD, discusses results of the AMPLIFY study. 16:30

Read the full coverage here:

Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia

Bicistronic CAR-T effective for children with relapsed B-ALL

VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia

First-line regimen improves PFS in chronic lymphocytic leukemia

Epcoritamab exhibits ‘very encouraging’ efficacy in heavily pretreated CLL

Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL

Disclosures:

Albliwi reports no relevant financial disclosures.

Danilov reports research funding from and/or consulting roles with AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen and other companies. Please see the abstract for all other researchers’ relevant financial disclosures.

Gerds reports consulting roles with AbbVie, Bristol Myers Squibb, Disc Medicine, GSK, PharmaEssentia and Rain Oncology. Please see the abstract for all other researchers’ relevant financial disclosures.

Greenberger reports no relevant financial disclosures.

Rau reports consulting/advisory roles with and/or honoraria from Jazz Pharmaceuticals and Servier. She also reports her spouse is employed by AbbVie. Please see the abstract for all other researchers’ relevant financial disclosures.

Zhang reports no relevant financial disclosures.